Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation

• الحاوية / القاعدة: Scientific Reports
• المؤلفون الرئيسيون: Ayana Fujiwara, Keisuke Takemura, Anna Tanaka, Misaki Matsumoto, Masato Katsuyama, Takeshi Okanoue, Kanji Yamaguchi, Yoshito Itoh, Kazumi Iwata, Kikuko Amagase, Atsushi Umemura
• التنسيق: مقال
• اللغة: الإنجليزية
• منشور في: Nature Portfolio 2024-08-01
• الموضوعات: Proteasome inhibitor; Carfilzomib; Hepatic stellate cell; Liver fibrosis
• الوصول للمادة أونلاين: https://doi.org/10.1038/s41598-024-70296-8

Abstract Because hepatic stellate cells (HSCs) play a major role in fibrosis, we focused on HSCs as a potential target for the treatment of liver fibrosis. In this study, we attempted to identify drug candidates to inactivate HSCs and found that several proteasome inhibitors (PIs) reduced HSC viability. Our data showed that a second-generation PI, carfilzomib (CZM), suppressed the expression of fibrotic markers in primary murine HSCs at low concentrations of 5 or 10 nM. Since CZM was not toxic to HSCs up to a concentration of 12.5 nM, we examined its antifibrotic effects further. CZM achieved a clear reduction in liver fibrosis in the carbon tetrachloride (CCl4)-induced mouse model of liver fibrosis without worsening of liver injury. Mechanistically, RNA sequence analysis of primary HSCs revealed that CZM inhibits mitosis in HSCs. In the CCl4-injured liver, amphiregulin, which is known to activate mitogenic signaling pathways and fibrogenic activity and is upregulated in murine and human metabolic dysfunction-associated steatohepatitis (MASH), was downregulated by CZM administration, leading to inhibition of mitosis in HSCs. Thus, CZM and next-generation PIs in development could be potential therapeutic agents for the treatment of liver fibrosis via inactivation of HSCs without liver injury.